Scilex Holding (NASDAQ:SCLX) Bolsa

Scilex Holding

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Scilex Holding Co

JP Morgan analyst Doug Anmuth maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Neutral and raises the price target from $58 to $60.

News

Price Target

Analyst Ratings

EBAY

JP Morgan Maintains Neutral on eBay, Raises Price Target to $60

JP Morgan analyst Pinjalim Bora maintains Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) with a Overweight and raises the price target from $83 to $90.

NTNX

JP Morgan Maintains Overweight on Nutanix, Raises Price Target to $90

Buybacks

GFL Environmental Say TSX Accepted Notice Of Intention To Commence Normal Course Issuer Bid

2025 guidance summary
<ul>
<li>GAAP revenue growth guidance range of (0.4)% to 0.7%</li>
<li>Adjusted constant currency revenue growth guidance range of 1.0% to 2.0%, which excludes the 2024 impact from increases in our reserves related to the Italian payback measure pertaining to prior years</li>
<li>GAAP EPS from continuing operations guidance range of $8.85 to $9.25.</li>
<li>Adjusted diluted EPS from continuing operations guidance range of $13.95 to $14.35</li>
</ul>
"In the fourth quarter, we delivered strong double-digit adjusted earnings per share growth" said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "The benefits of our diversified portfolio were evident as strong performances from Interventional and Surgical helped offset softness in Interventional Urology revenues. Palette Life Sciences revenues exceeded $75 million in 2025, which was above the $73-$75 million guidance. As announced in a separate press release today, we also took an important step forward in our durable growth strategy with the agreement to acquire substantially all of BIOTRONIK's Vascular Intervention business. This acquisition provides us with a diversified suite of products of coronary and peripheral interventions devices, which complements the Teleflex Interventional business. Also announced today in a separate press release is our intention to separate Teleflex into two publicly traded companies, RemainCo and NewCo. The separation is expected to simplify the operating model, streamline the manufacturing footprint, and increase management focus of each company."

Earnings

Guidance

Health Care

General

Teleflex Expects 2025 Revenue Growth Of (0.4)% To 0.7%, With Adjusted EPS Of $13.95-$14.35 Versus Consensus Of $15.23

JP Morgan analyst Seth Seifman maintains Kratos Defense &amp; Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) with a Neutral and raises the price target from $24 to $27.

KTOS

JP Morgan Maintains Neutral on Kratos Defense & Security, Raises Price Target to $27

Based on the above framework,&nbsp;GFL expects 2028 revenue could be between C$9.240 billion and C$9.490 billion and 2028 Adjusted EBITDA could be between C$3.045 billion and C$3.120 Billion.
 &nbsp;

GFL Environmental To Present Its 2028 Financial Framework, Annual Organic Revenue Growth Of Approximately 5.0% To 6.0%

JP Morgan analyst Tien-Tsin Huang maintains AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) with a Neutral and lowers the price target from $10 to $9.

AVDX

JP Morgan Maintains Neutral on AvidXchange Holdings, Lowers Price Target to $9

APP CLIMBS OVER 1.4% AFTER ALERT AND REVERSES EARLY WEAKNESS
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/26213151/Screenshot-2025-02-26-at-4.26.13%E2%80%AFPM-1024x943.png" alt="" class="wp-image-6713" style="width:920px;height:auto" /></figure>
Applovin, Inc. (APP) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:18 AM on February 26th, a significant trading signal occurred for Applovin, Inc. (APP) as it demonstrated a Power Inflow at a price of $299.87. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Applovins stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Applovin&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for APP, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $299.87. The returns on the High price ($342.35) and Close price ($331.00) after the Power Inflow were respectively 1.4% and 1.0%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Equities

Technicals

Signals

AppLovin Stock Moves Up After This Key Trading Signal

First Advantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FA#NASDAQ">FA</a>) is looking for FY2025 Adj EPS of $0.86-$1.03 vs $1.00 analyst estimate. sees sales of $1.500 billion-$1.600 billion vs $1.49 billion analyst estimate.

First Advantage Sees FY2025 Adj EPS $0.86-$1.03 vs $1.00 Est; Sees Sales $1.500B-$1.600B vs $1.49B Est

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) reported quarterly earnings of $3.89 per share which beat the analyst consensus estimate of $3.86 by 0.78 percent. This is a 15.09 percent increase over earnings of $3.38 per share from the same period last year. The company reported quarterly sales of $795.41 million which missed the analyst consensus estimate of $813.23 million by 2.19 percent. This is a 2.78 percent increase over sales of $773.90 million the same period last year.

Teleflex Q4 2024 Adj EPS $3.89 Beats $3.86 Estimate, Sales $795.41M Miss $813.23M Estimate

First Advantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FA#NASDAQ">FA</a>) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.23 by 21.74 percent. This is a 37.93 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $307.12 million which beat the analyst consensus estimate of $304.82 million by 0.76 percent. This is a 51.62 percent increase over sales of $202.56 million the same period last year.

Earnings Beats

Earnings Misses

First Advantage Q4 Adj $0.18 Misses $0.23 Estimate, Sales $307.12M Beat $304.82M Estimate

HC Wainwright &amp; Co. analyst Andrew Fein maintains Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and lowers the price target from $47 to $40.

KROS

HC Wainwright & Co. Maintains Buy on Keros Therapeutics, Lowers Price Target to $40

&nbsp;Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition.

Management

Teleflex Announced That Thomas Powell Will Retire As EVP And CFO, Effective April 1. John Deren, Currently The Corporate Vice President And Chief Accounting Officer Of Teleflex, Will Become EVP And CFO, Effective April 2

Contracts

VIAV

VIAVI, AT&T And Verizon Reveal Collaboration To Accelerate Testing Of Open RAN; Terms Not Disclosed

OUTLOOK
Veren has had a strong start to 2025, generating 191,000 boe/d of production in January. The Company remains on track to meet its previously released full year annual average production guidance of 188,000 to 196,000 boe/d (65% oil and liquids), based on its development capital expenditures budget of $1.48 billion to $1.58 billion. Veren's capital program is weighted to the first half of 2025, while its production is weighted to the second half of the year due to the timing of its development program and planned facilities downtime in early 2025. The Company will remain disciplined in the execution of its capital program, with the flexibility to adjust spending in response to market conditions in order to maximize long-term shareholder value.

Veren FY25 Average Production Guidance Of 188,000-196,000 Boe/d

The Chinese government is making efforts towards early stage discussions with the U.S. military, a move that could signal an easing of the recent tensions.
What Happened: China&#8217;s Defense Ministry spokesman Wu Qian announced the preliminary plans for talks during a regular briefing in Beijing, Bloomberg <a href="https://www.bloomberg.com/news/newsletters/2025-02-27/china-plans-us-military-talks-lifting-hopes-tensions-may-ease">reported</a> on Thursday. While details are still sparse, Wu announced that further details will be shared soon.
"It is hoped that China-U.S. military-to-military relations get off to a good start and continue to grow further," stated the spokesperson. 
On Feb 13, President Donald Trump expressed his intentions of nuclear arms control talks with China and Russia, as well as suggested that all three countries must cut their defense budgets by half. Trump stated that "de-nuclearize" is a "beautiful term." &#8220;&#8230;there&#8217;s no reason for us to be spending almost $1 trillion on the military,&#8221; the U.S. President emphasized.
In response to this, Wu Qian said, &#8220;I believe that the United States should put into practice &#8216;America First&#8217; in this regard, and be the first to cut its nuclear arsenal and military expenditure,&#8221;&nbsp;according to a report by Xinhua News. 
At the same time, Wu reaffirmed China&#8217;s commitment to a no-first-use policy on nuclear weapons, emphasizing its self-defensive nuclear strategy and maintaining its nuclear capabilities at the minimal level necessary for national security.
SEE ALSO:<a href="https://www.benzinga.com/news/contracts/25/02/44000716/nasdaq-secures-deal-to-upgrade-austrias-regulatory-reporting-infrastructure"> </a><a href="https://www.benzinga.com/news/contracts/25/02/44000716/nasdaq-secures-deal-to-upgrade-austrias-regulatory-reporting-infrastructure">Nasdaq Secures Deal To Upgrade Austria&#8217;s Regulatory Reporting Infrastructure</a>
Why It Matters: Wu&#8217;s announcement comes on the heels of Trump&#8217;s return as the U.S. President and amid escalating tensions between the two countries over issues such as semiconductor <a href="https://www.benzinga.com/markets/25/02/43938959/trump-targets-chinas-tech-sector-with-stricter-biden-era-chip-curbs-it-will-backfire-says-beijing">access, investment, and tariffs</a>.
The proposed talks could potentially alleviate some of these conflicts. Responding to the Trump&nbsp;administration&#8217;s initial moves, China has strategically targeted <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43454424/china-strikes-back-new-tariffs-up-to-15-on-certain-us-imports-in-retaliation-for-trumps-10-levy-on-chinese-goods">U.S. products with tariffs</a>, while also indicating that it has additional measures at its disposal to affect American companies if necessary.
That being said, Beijing and Washington seem eager to keep their differences from escalating further. President Trump has even hinted at a possible trade deal with China and expressed his interest in speaking with Chinese leader&nbsp;Xi Jinping.
<ul>
<li>READ MORE:<a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44000111/jim-cramer-says-misunderstood-robinhood-stock-not-merely-a-crypto-play-its-an-investment-in-the-way-the-next-generations-will-invest"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44000111/jim-cramer-says-misunderstood-robinhood-stock-not-merely-a-crypto-play-its-an-investment-in-the-way-the-next-generations-will-invest">Jim Cramer Says &#8216;Misunderstood&#8217; Robinhood Stock Not Merely A Crypto Play: &#8216;It&#8217;s An Investment In The Way The Next Generations Will Invest&#8217;</a></li>
</ul>
Photo by asiandelight on Shutterstock

Politics

Economics

Markets

China, US To Begin Military Talks, Signaling Possible De-escalation—Beijing Urges 'America First' In Nuclear Disarmament

Veren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRN#NYSE">VRN</a>) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.24 by 19.17 percent. This is a 5.93 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $739.39 million which beat the analyst consensus estimate of $694.02 million by 6.54 percent. This is a 6.30 percent increase over sales of $695.58 million the same period last year.

Veren Q4 Adj EPS $0.29 Beats $0.24 Estimate, Sales $739.39M Beat $694.02M Estimate

PLTK

Playtika Sees FY25 Revenue $2.8B-$2.85B vs $2.751B Est.

Nuvalent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.08) by 2.78 percent. This is a 69.35 percent decrease over losses of $(0.62) per share from the same period last year.

NUVL

Nuvalent Q4 2024 GAAP EPS $(1.05) Beats $(1.08) Estimate

Playtika Holding Q4 2024 GAAP EPS $(0.04), Sales $650.300M Beat $631.023M Estimate

Press Releases

Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication

Dividends

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

DECA

SCLX

SRNE

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

CalciMedica

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Grace Therapeutics

Ikena Oncology

Opus Genetics

Iterum Therapeutics

Lexaria Bioscience

NRX Pharmaceuticals

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

SCYNEXIS

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

VYNE Therapeutics

D. Boral Capital

HC Wainwright & Co.

Alliance Global Partners

Rodman & Renshaw

B. Riley Securities

Semnur Pharmaceuticals, Inc., A Wholly Owned Subsidiary Of Scilex Holding Company, Announces Today The Filing Of A Registration Statement On Form S-4 by Denali Capital Acquisition Corp. With The Securities And Exchange Commission Relating To The Previously Announced Proposed Business Combination Between Semnur And Denali

Skyscrapers,Cityscape,Downtown,View,,Nashville,Skyline,Buildings.,Beautiful,Real,Estate.

Scilex Holding Company Announces Signing Of A $50 Million Registered Convertible Financing To Refinance And Restructure Existing Debt &amp; Further Strengthens Financial Profile

United,States,Bankruptcy,Court,Sign

Biotech

SRNEQ

Scilex Holding Company Announces That The U.S. Bankruptcy Court Has Extended The Lockup Period On Shares Of Scilex Dividend Stock Previously Distributed By Sorrento To Its Stockholders As A Dividend To January 31, 2025

Business,Analyst,Checking,In,Financial,Statement,For,Audit,Internal,Control

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

Hand,Of,Human,Holding,Crystal,Globe,Ball,With,Tree,For

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Business,Man,Sign,A,Contract,Investment,Professional,Document,Agreement.,Meeting

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Businessmen,Making,Handshake,With,Partner,,Greeting,,Dealing,,Merger,And,Acquisition,

Scilex Holding Company Partners With New National Distributor, Endeavor Distribution LLC.

Muscular,Man,Suffering,From,Back,And,Neck,Pain.,Incorrect,Sitting

Scilex Holding Company Announces Publication In PAIN Journal Regarding Phase 3 Results Of The Pivotal Registration Trial Of SP-102 (SEMDEXA™) In Lumbosacral Radicular Pain (Sciatica)

Outside,Of,Logistics,Warehouse,With,Open,Door,,Delivery,Van,Loaded

Scilex Holding Company Announces That Many National Pharmacy Chains And Independent Pharmacies Have Begun Stocking GLOPERBA®

Interior,Of,A,Modern,Warehouse,Storage,Of,Retail,Shop,With

Scilex Holding Company Announces Stocking Of GLOPERBA® Is Underway In All Of The Wholesalers With Which Scilex Has Stocking Arrangements Throughout The U.S.

Comments

Scilex Holding

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL